Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
Recruiting · NCT07722741 · Registry updated 2026-09-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC | hepatocellular carcinoma | Recruiting | Phase 2 | 2026-09-23 | NCT07722741 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Geneos Therapeutics | 3 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Auckland City Hospital (Te Toka Tumai) | Auckland | New Zealand | 1 |
| Emory University | Atlanta | United States | 262 |
| Fred Hutchinson Cancer Center | Seattle | United States | 250 |
| Icahn School of Medicine at Mount Sinai | New York | United States | 342 |
| Johns Hopkins University | Baltimore | United States | 150 |
| Louisiana State University Health Sciences Center | New Orleans | United States | 10 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| New York Presbyterian Hospital-Columbia University Irving Medical Center | New York | United States | 1 |
| University of Michigan | Ann Arbor | United States | 538 |